RE:RE:RE:AACR Poster - very interestingIt will certainly make the investor call they are planning more meaningful as had that data not been available we would be left wondering about some aspects of the trial. So, having all that data will be really helpful. Now, it has the potential to both increase or decrease our confidence in the restarted trial but at least we will go into it better informed.
Wino115 wrote: They got all the data together for the new protocal and the Scientific Adv Committee review and decision on whether to proceed and how. Typically you'd compile for a paper, but perhaps since they had to compile it all for the revision, FDA and that SAC, that is the data the investigator decided to publish and talk about. I was certain they would only cover the first part of the trial since that followed the procedures and they had 100% of the data from it. I thougth they'd skip the second part since it was partial data and then just do one more after that data was fully gathered. So this is a surprise to me that they are reviewing all 38 patients that were on it for a few cycles. Will be really interesting to see the data now just to see what they are basing their decisions on.